e-learning
resources
European Respiratory Review
2013
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Immunosuppression for interstitial lung disease in systemic sclerosis},
Susanna Cappelli, Serena Guiducci, Silvia Bellando Randone, Marco Matucci Cerinic
Source:
Eur Respir Rev 2013; 22: 236-243
Journal Issue:
September 2013 - 22 (129)
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Susanna Cappelli, Serena Guiducci, Silvia Bellando Randone, Marco Matucci Cerinic. Immunosuppression for interstitial lung disease in systemic sclerosis},. Eur Respir Rev 2013; 22: 236-243
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy},
Source: Eur Respir J 2012; 40: 641-648
Year: 2012
Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis
Source: Eur Respir J 2011; 38: 1355-1360
Year: 2011
Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Interstitial lung disease in systemic sclerosis: where do we stand?
Source: Eur Respir Rev 2015; 24: 411-419
Year: 2015
Pulmonary hypertension in chronic interstitial lung diseases},
Source: Eur Respir Rev 2013; 22: 292-301
Year: 2013
Predictors of progression in systemic sclerosis patients with interstitial lung disease
Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019
Year: 2020
The natural course of systemic sclerosis patients with interstitial lung involvement
Source: Eur Respir J 2005; 26: Suppl. 49, 336s
Year: 2005
Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease
Source: Eur Respir Rev, 27 (148) 170102; 10.1183/16000617.0102-2017
Year: 2018
Rituximab in severe, progressive interstitial lung disease
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Year: 2019
Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020
Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Rituximab in severe, treatment-refractory interstitial lung disease
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Disease course and outcome of progressive interstitial lung disease in systemic sclerosis
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Year: 2019
Longitudinal functional evaluation of interstitial lung disease in systemic sclerosis
Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Analysis of inflammatory networks in interstitial lung disease in patients with rheumatoid arthritis
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
IL-17+ cells immunoexpression in systemic sclerosis pulmonary fibrosis
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Anti-a-enolase antibodies in systemic sclerosis identify a subset of patients with diffuse cutaneous sclerosis and interstitial lung disease
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept